ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Stock Has Average Price Target of $35.00 According to Analysts

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) has received an average rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $35.00.

ADRX has been the topic of several research analyst reports. Zacks Research upgraded ADARx Pharmaceuticals to a “hold” rating in a report on Wednesday, October 21st. Morgan Stanley initiated coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They set an “overweight” rating and a $32.00 target price on the stock. UBS Group began coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They issued a “buy” rating and a $35.00 price target for the company. TD Cowen started coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They issued a “buy” rating for the company. Finally, Wall Street Zen upgraded ADARx Pharmaceuticals to a “hold” rating in a report on Saturday, October 3rd.

ADARx Pharmaceuticals Price Performance

NASDAQ ADRX opened at $17.85 on Friday. ADARx Pharmaceuticals has a twelve month low of $16.61 and a twelve month high of $23.21.

Insider Buying and Selling at ADARx Pharmaceuticals

In other news, major shareholder Sr One Capital Management, Llc bought 1,600,000 shares of ADARx Pharmaceuticals stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the completion of the acquisition, the insider directly owned 5,554,094 shares in the company, valued at $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Simeon George purchased 1,600,000 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The stock was purchased at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the purchase, the director directly owned 5,554,094 shares of the company’s stock, valued at $94,419,598. The trade was a 40.46% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 3,261,516 shares of company stock valued at $55,445,772 in the last quarter.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.